ロード中...
Estimating the cost-effectiveness of a sequential pneumococcal vaccination program for adults in Germany
INTRODUCTION: In Germany, a 23-valent polysaccharide pneumococcal vaccine (PPSV23) is recommended for elderly (60+) and patients 16+ with chronic diseases not associated with immune suppression. For all other patients at risk, sequential immunization with a 13-valent pneumococcal conjugate vaccine (...
保存先:
| 出版年: | PLoS One |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Public Library of Science
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5967715/ https://ncbi.nlm.nih.gov/pubmed/29795647 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0197905 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|